Every year, thousands of patients sit in doctors’ offices with needles in their arms receiving a dose of a wonder drug called Keytruda. The cancer medicine is one of the world’s best sellers, earning Merck $29.5bn in sales last year. But drip by drip, the US pharmaceutical company’s time is running out.
每年，成千上万的患者坐在医生办公室，手臂上插着针，接受一种名为可瑞达(Keytruda)的神奇药物治疗。这款癌症药物是manbetx app苹果 最畅销的药物之一，去年为默克(Merck)带来了295亿美元的销售额。但随着一滴滴药液注入，默克的专利保护期也在逐渐流逝。
您已阅读2%（426字），剩余98%（21180字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。